- Home
- SBRA vs CRSP Comparison
SBRA vs CRSP Comparison
Compare SBRA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | CRSP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.8B |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SBRA | CRSP |
|---|---|---|
| Price | $19.88 | $50.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 23 |
| Target Price | $22.36 | ★ $85.63 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 11-02-2026 | 11-13-2026 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | ★ 18.52 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $774,632,000.00 | $289,590,000.00 |
| Revenue This Year | $19.43 | $1,052.09 |
| Revenue Next Year | $10.46 | $280.75 |
| P/E Ratio | $329.08 | ★ N/A |
| Revenue Growth | 10.15 | ★ 9169.85 |
| 52 Week Low | $17.54 | $44.12 |
| 52 Week High | $22.81 | $63.45 |
Technical Indicators
Market Signals| Indicator | SBRA | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 45.59 |
| Support Level | $19.54 | $50.02 |
| Resistance Level | $20.90 | $60.68 |
| Average True Range (ATR) | 0.42 | 2.32 |
| MACD | 0.10 | 0.27 |
| Stochastic Oscillator | 87.50 | 37.71 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.